https://www.mynewsdesk.com/se/astellas-pharma Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. https://www.mynewsdesk.com/se/astellas-pharma https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Mon, 08 Dec 2025 09:00:00 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/nt-raadet-rekommenderar-vyloy-i-kombination-med-kemoterapi-vid-cancer-i-magsaecken-eller-gastroesofageala-oevergaangen-3420383?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/nt-raadet-rekommenderar-vyloy-i-kombination-med-kemoterapi-vid-cancer-i-magsaecken-eller-gastroesofageala-oevergaangen-3420383?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Wed, 20 Aug 2025 09:02:45 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/padcev-enfortumab-vedotin-plus-keytruda-pembrolizumab-significantly-improves-survival-for-certain-patients-with-bladder-cancer-when-given-before-and-after-surgery-3399869?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/padcev-enfortumab-vedotin-plus-keytruda-pembrolizumab-significantly-improves-survival-for-certain-patients-with-bladder-cancer-when-given-before-and-after-surgery-3399869?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Thu, 26 Sep 2024 09:32:53 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-godkaenner-astellas-vyloy-zolbetuximab-i-kombination-med-kemoterapi-foer-behandling-av-avancerad-magsaeckscancer-och-cancer-i-den-gastroesofageala-oevergaangen-3345233?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-godkaenner-astellas-vyloy-zolbetuximab-i-kombination-med-kemoterapi-foer-behandling-av-avancerad-magsaeckscancer-och-cancer-i-den-gastroesofageala-oevergaangen-3345233?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Tue, 03 Sep 2024 09:08:35 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-godkaenner-astellas-padcev-enfortumab-vedotin-i-kombination-med-keytruda-r-pembrolizumab-som-foersta-linjens-behandling-vid-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3340296?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-godkaenner-astellas-padcev-enfortumab-vedotin-i-kombination-med-keytruda-r-pembrolizumab-som-foersta-linjens-behandling-vid-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3340296?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Wed, 28 Aug 2024 08:00:00 +0200 Varför är det så svårt att prata om något som berör halva befolkningen? En nyligen genomförd Novus-undersökning visar att många kvinnor känner oro, har begränsad kunskap, tycker det är svårt att prata om klimakteriet och vet oftast inte ens vart de ska vända sig för att få hjälp. Välkommen till Klimakteriesnacket- ett kostnadsfritt, livestreamat samtal för alla som vill lära mer om klimakteriet. https://www.mynewsdesk.com/se/astellas-pharma/news/vaelkommen-till-klimakteriesnacket-487339?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/news/vaelkommen-till-klimakteriesnacket-487339?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Wed, 31 Jul 2024 09:50:36 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-faar-positivt-chmp-utlaatande-foer-zolbetuximab-i-kombination-med-kemoterapi-foer-behandling-av-avancerad-magsaeckscancer-och-cancer-i-den-gastroesofageala-oevergaangen-3335796?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-faar-positivt-chmp-utlaatande-foer-zolbetuximab-i-kombination-med-kemoterapi-foer-behandling-av-avancerad-magsaeckscancer-och-cancer-i-den-gastroesofageala-oevergaangen-3335796?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Fri, 05 Jul 2024 08:30:00 +0200 Svenska kvinnor googlar hellre än att fråga vården enligt en ny Novus-undersökning om klimakteriet. 34% upplever sig ha ingen eller begränsad kunskap om klimakteriet och 57% anser att deras kunskap om behandlingsalternativ är begränsad. Nästan hälften av kvinnorna att de känner oro relaterat till klimakteriebesvär, vilket påverkar både arbets- och privatlivet. Stödet från vården behöver öka. https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/klimakteriet-beroer-haelften-av-befolkningen-ny-novus-undersoekning-visar-paa-behovet-av-oekat-stoed-och-kunskap-fraan-vaarden-3333259?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/klimakteriet-beroer-haelften-av-befolkningen-ny-novus-undersoekning-visar-paa-behovet-av-oekat-stoed-och-kunskap-fraan-vaarden-3333259?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Fri, 17 May 2024 12:26:46 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/tlv-beslut-veoza-ingaar-i-hoegkostnadsskyddet-foer-patienter-som-inte-kan-behandlas-med-hormoner-3323673?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/tlv-beslut-veoza-ingaar-i-hoegkostnadsskyddet-foer-patienter-som-inte-kan-behandlas-med-hormoner-3323673?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Fri, 22 Mar 2024 14:34:45 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/chmp-rekommenderar-xtandi-enzalutamid-foer-behandling-av-hoegriskpatienter-med-aaterfall-vid-tidig-prostatacancer-i-eu-3312635?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/chmp-rekommenderar-xtandi-enzalutamid-foer-behandling-av-hoegriskpatienter-med-aaterfall-vid-tidig-prostatacancer-i-eu-3312635?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Tue, 12 Dec 2023 11:46:42 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-kommissionen-godkaenner-veoza-fezolinetant-foer-behandling-av-maattliga-till-svaara-vasomotoriska-symtom-vms-i-samband-med-menopaus-3292518?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/eu-kommissionen-godkaenner-veoza-fezolinetant-foer-behandling-av-maattliga-till-svaara-vasomotoriska-symtom-vms-i-samband-med-menopaus-3292518?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Sun, 22 Oct 2023 16:30:00 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/resultat-fraan-fas-3-studie-ev-302-visar-signifikant-foerlaengd-oeverlevnad-foer-behandling-med-padcev-enfortumab-vedotin-i-kombination-med-keytruda-r-pembrolizumab-hos-patienter-med-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3281210?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/resultat-fraan-fas-3-studie-ev-302-visar-signifikant-foerlaengd-oeverlevnad-foer-behandling-med-padcev-enfortumab-vedotin-i-kombination-med-keytruda-r-pembrolizumab-hos-patienter-med-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3281210?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Thu, 19 Oct 2023 09:23:13 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/new-england-journal-of-medicine-publicerar-astellas-resultat-fraan-fas-iii-studien-embark-som-utvaerderar-xtanditm-enzalutamid-hos-hoegriskpatienter-efter-biokemiskt-aaterfall-med-icke-metastaserad-prostatacancer-3280666?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/new-england-journal-of-medicine-publicerar-astellas-resultat-fraan-fas-iii-studien-embark-som-utvaerderar-xtanditm-enzalutamid-hos-hoegriskpatienter-efter-biokemiskt-aaterfall-med-icke-metastaserad-prostatacancer-3280666?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Mon, 16 Oct 2023 12:26:03 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-to-share-new-data-across-hard-to-treat-cancers-during-esmo-congress-2023-3279837?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-to-share-new-data-across-hard-to-treat-cancers-during-esmo-congress-2023-3279837?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Mon, 16 Oct 2023 07:30:00 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/chmp-rekommenderar-veozatm-fezolinetant-foer-godkaennande-i-eu-3279729?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/chmp-rekommenderar-veozatm-fezolinetant-foer-godkaennande-i-eu-3279729?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Wed, 05 Jul 2023 13:02:36 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/positiva-topline-resultat-fraan-fas-3b-studie-med-fezolinetant-foer-behandling-av-vaermevallningar-och-slash-eller-nattsvettningar-vasomotoriska-symptom-vms-vid-menopaus-3263474?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/positiva-topline-resultat-fraan-fas-3b-studie-med-fezolinetant-foer-behandling-av-vaermevallningar-och-slash-eller-nattsvettningar-vasomotoriska-symptom-vms-vid-menopaus-3263474?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Thu, 29 Jun 2023 15:43:26 +0200 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/underhaallsbehandling-med-gilteritinib-foerdelaktigt-foer-subgrupp-av-patienter-med-flt3-positiv-akut-myeloisk-leukemi-3262629?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/underhaallsbehandling-med-gilteritinib-foerdelaktigt-foer-subgrupp-av-patienter-med-flt3-positiv-akut-myeloisk-leukemi-3262629?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Thu, 23 Mar 2023 15:57:37 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/xtandi-enzalutamid-och-leuprorelin-i-kombination-foerbaettrar-signifikant-metastasfri-oeverlevnad-hos-patienter-med-icke-metastaserad-prostatacancer-enligt-fas-iii-studien-embark-3241900?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/xtandi-enzalutamid-och-leuprorelin-i-kombination-foerbaettrar-signifikant-metastasfri-oeverlevnad-hos-patienter-med-icke-metastaserad-prostatacancer-enligt-fas-iii-studien-embark-3241900?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Wed, 22 Mar 2023 09:50:32 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-announces-positive-findings-from-phase-3-glow-trial-of-zolbetuximab-during-march-asco-plenary-series-3241312?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/astellas-announces-positive-findings-from-phase-3-glow-trial-of-zolbetuximab-during-march-asco-plenary-series-3241312?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Tue, 24 Jan 2023 09:28:17 +0100 https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/asco-gi-astellas-presenterar-positiva-resultat-foer-zolbetuximab-fraan-fas-3-studien-spotlight-3229291?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/asco-gi-astellas-presenterar-positiva-resultat-foer-zolbetuximab-fraan-fas-3-studien-spotlight-3229291?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma Mon, 09 Jan 2023 08:59:23 +0100 NT-rådet rekommenderar användande av PADCEV som monoterapi vid behandling av vuxna patienter med lokalt avancerad eller metastaserad urotelial cancer som tidigare har fått platinainnehållande kemoterapi och en PD-(L)1-hämmare. https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/nt-raadet-rekommenderar-padcev-som-monoterapi-vid-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3226545?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/astellas-pharma/pressreleases/nt-raadet-rekommenderar-padcev-som-monoterapi-vid-lokalt-avancerad-eller-metastaserad-urotelial-cancer-3226545?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Astellas Pharma